Cases & Deals

  • Home
  • Practices
  • Johnson & Johnson announces $438 million acquisition of Omrix Biopharmaceuticals

Share

Johnson & Johnson announces $438 million acquisition of Omrix Biopharmaceuticals

December 2008

Clients Johnson & Johnson

Jones Day acted as tax counsel to Johnson & Johnson in its approximately $438 million acquisition of Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. The acquisition was completed on December 30, 2008.

Contacts

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.